Summary
39.91 0.45(1.14%)07/03/2025
Ultragenyx Pharmaceutical Inc. (RARE)
RARE reported last earnings on 2025-05-06 after the market. An EPS of $-1.57 was observed compared to an estimated EPS of $-1.54, resulting in a surprise value of $-0.03. A revenue of $139 million was observed compared to an estimated revenue of $162 million, resulting in a surprise value of $-23 Million.
Ultragenyx Pharmaceutical Inc. (RARE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 1.14 | 9.28 | 9.64 | 13.61 | -3.83 | -0.75 | -53.99 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Buy |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 39.91 | |
| Open | 39.57 | |
| High | 39.98 | |
| Low | 39.02 | |
| Volume | 685,300 | |
| Change | 0.45 | |
| Change % | 1.14 | |
| Avg Volume (20 Days) | 1,138,389 | |
| Volume/Avg Volume (20 Days) Ratio | 0.60 | |
| 52 Week Range | 30.18 - 60.37 | |
| Price vs 52 Week High | -33.89% | |
| Price vs 52 Week Low | 32.24% | |
| Range | 0.00 | |
| Gap Up/Down | -0.30 | |
Profitibility | ||
| Market Capitalization (Mln) | 3,485 | |
| Revenue per share | 6.1346 | |
| Net Income per share | -5.7076 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -6.9924 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/30 12:41 EST - zacks.com
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
06/27 08:00 EST - globenewswire.com
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that it...
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that it...
06/24 04:03 EST - globenewswire.com
RARE FERRARI BERLINETTAS LINE UP FOR INAUGURAL BROAD ARROW ZOUTE CONCOURS AUCTION
AUCTION TO FEATURE A 1967 FERRARI 275 GTB/4 FINISHED IN EXTREMELY RARE VERDE PINO | HIGHLY COLLECTIBLE 1970 FERRARI 365 GTB/4 DAYTONA “PLEXI” ONE OF ONLY TWO DELIVERED NEW IN AVORIO | AUCTION TO TAKE PLACE ON 10 OCTOBER 2025 IN COLLABORATION WITH ZOUTE GRAND PRIX CAR WEEK AUCTION TO FEATURE A...
RARE FERRARI BERLINETTAS LINE UP FOR INAUGURAL BROAD ARROW ZOUTE CONCOURS AUCTION
AUCTION TO FEATURE A 1967 FERRARI 275 GTB/4 FINISHED IN EXTREMELY RARE VERDE PINO | HIGHLY COLLECTIBLE 1970 FERRARI 365 GTB/4 DAYTONA “PLEXI” ONE OF ONLY TWO DELIVERED NEW IN AVORIO | AUCTION TO TAKE PLACE ON 10 OCTOBER 2025 IN COLLABORATION WITH ZOUTE GRAND PRIX CAR WEEK AUCTION TO FEATURE A...
06/20 16:30 EST - globenewswire.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the...
06/05 12:36 EST - zacks.com
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
06/03 17:00 EST - globenewswire.com
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the...
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the...
05/14 16:30 EST - globenewswire.com
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare...
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare...
05/08 08:01 EST - globenewswire.com
HENRY CATCHPOLE TAKES TO THE TRACK IN RARE HONDA NSX-R IN SWEDEN AHEAD OF BROAD ARROW'S FIRST EUROPEAN AUCTION
HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY
HENRY CATCHPOLE TAKES TO THE TRACK IN RARE HONDA NSX-R IN SWEDEN AHEAD OF BROAD ARROW'S FIRST EUROPEAN AUCTION
HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY
05/07 17:00 EST - globenewswire.com
Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief...
Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief...
05/07 11:45 EST - zacks.com
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
05/06 23:31 EST - seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
05/06 19:00 EST - zacks.com
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/06 18:10 EST - zacks.com
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.57 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $2.03 per share a year ago.
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.57 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $2.03 per share a year ago.
05/06 16:01 EST - globenewswire.com
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million
05/05 10:15 EST - zacks.com
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
04/30 17:00 EST - globenewswire.com
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at...
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at...
04/24 11:08 EST - zacks.com
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/16 09:49 EST - seekingalpha.com
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key...
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key...
04/10 10:30 EST - zacks.com
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.